Allero Therapeutics develops next generation immunotherapies for allergic and autoimmune disease patients, with a focus on food-related immune disorders. Based on research by the founders and their collaborators the team has identified a novel specific immunotherapy approach based on antigen-specific tolerance induction.The company’s proprietary SOMIT (Specific OroMucosal ImmunoTherapy) technology is designed to induce long-lasting antigen-specific tolerance.
Biotechnology, Pharmaceutical, Immunotherapy
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Allero Therapeutics? We’re happy to assist you with our Startup Sourcing service.